PACIFIC EDGE LIMITED (PEB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PEB

PEB - PACIFIC EDGE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.23

17 Jul
2026

-0.015

OPEN

$0.25

-6.12%

HIGH

$0.25

25,036

LOW

$0.23

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-3.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx10.2 M
Book Value Per Share xxxxxxxxxxxxxxx0.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-28.4 M
Net Profit Margin xxxxxxxxxxxxxxx-311.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-195.13 %
Return on Invested Capital xxxxxxxxxxxxxxx-188.29 %
Return on Assets xxxxxxxxxxxxxxx-131.60 %
Return on Equity xxxxxxxxxxxxxxx-195.13 %
Return on Total Capital xxxxxxxxxxxxxxx-185.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-28.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx6 M
Price To Book Value xxxxxxxxxxxxxxx16.70

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx1.15 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx33 M
Research & Development xxxxxxxxxxxxxxx12 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

20/07/2026

3

Neutral

$0.20

-13.04%

Jarden maintains a Neutral rating for Pacific Edge with an unchanged target price of $0.20 following the release of Q1 27 volume and metric updates.

The broker highlights that clinical trial and investigator-initiated trial volumes fell 82% over the quarter, contributing to an overall 8.3% decline in total laboratory throughput to 5,116 tests.

In contrast, the APAC business shows strong momentum with commercial tests up 12.9%, approaching profitability on a direct-cost basis.

US test volumes declined 2.4% following a reduction in the sales force to 5.0 full-time equivalents, and the company is implementing a new sales strategy to reverse this trend.

Management anticipates a final local coverage determination before the end of 2026, with the regulatory timeline requiring finalisation or withdrawal by 14 May 2027.
Access Extra Coverage Research History >

PEB STOCK CHART

FNArena News on PEB

1
Australian Broker Call *Extra* Edition – Jul 20, 2026

Jul 20 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 28, 2026

May 28 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 13, 2026

May 13 2026 - Daily Market Reports
4
July In Review: Energy And Banks Drive Gains

Aug 03 2023 - Australia
5
FNArena Corporate Results Monitor – 02-06-2023

Jun 02 2023 - Australia

Latest Medical Equipment & Devices News

1
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
2
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
3
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
4
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
5
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
6
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
7
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
8
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
9
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
10
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest